tbuckley/cabot-search huggingface dataset:
Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank
Authors: Anika Knuppel, Georgina K. Fensom, Eleanor L. Watts, Marc J. Gunter, Neil Murphy, Keren Papier, Aurora Perez-Cornago, Julie A. Schmidt, Karl Smith Byrne, Ruth C. Travis, Timothy J. Key
Journal: Cancer Research (2020)

Abstract Circulating insulin-like growth factor I (IGF-I) is positively associated with the risks of colorectal, breast, and prostate cancer, but evidence for other less common cancers is limited. In this study, we investigated associations between serum IGF-I concentrations and incidence of less common cancers in the UK Biobank study. To enable comparison of effect estimates, and as positive controls, both common and less common cancer sites (total 30) were included in an outcome-wide analysis. Data from 394,388 cancer-free participants in the UK Biobank study were analyzed. Multivariable adjusted Cox proportional hazards models were used to determine associations between baseline serum IGF-I concentrations and cancer incidence, using repeated IGF-I measurements from up to 14,149 participants to correct for regression dilution bias. Higher IGF-I concentration was associated with increased risks of thyroid cancer [HR per 5 nmol/L higher concentration 1.18; 95% confidence interval (CI), 1.01–1.37] in addition to colorectal (HR, 1.08; 95% CI, 1.03–1.13), breast (HR, 1.11; 95% CI, 1.07–1.15), and prostate cancer (HR, 1.08; 95% CI, 1.05–1.12), and reduced risks of ovarian and liver cancer. Mean follow-up was 6.9 years and the possibility that the observed associations may be influenced by reverse causality bias cannot be excluded. Additional nominally significant associations with malignant melanoma, multiple myeloma, oral cancer, and esophageal squamous cell carcinoma did not survive correction for multiple testing. Studies with longer follow-up and pooled analyses are needed to further assess how broad the role of IGF-I is in cancer development. Significance: The results from this outcome-wide analysis are consistent with a positive association of IGF-I with cancers at several sites.
THU0233 Hypermobility syndrome – a disease or not a disease
Authors: Y Gazit, AM Nahir
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Although benign joint hypermobility syndrome (BJHS) is very common in the general population, the diagnosis is frequently missed. The reasons may be that BJHS is not a life threatening condition and most BJHS patients conduct normal life. Unfortunatly, most BJHS patients are frustrated, wandering from one physician to the other. <h3>Objectives</h3> To evaluate whether people with BJHS regard themselves as healthy or ill. <h3>Methods</h3> Forty people were diagnosed as having BJHS in a rheumatology clinic and were compared to 26 healthy controls. A skilled rheumatologist reviewed and examined all of them and fulfilled a questionnaire about their articular and non articular complaints as well as their well being. The questionnairs were statistically analysed. <h3>Results</h3> All BJHS patients were working and conducing active life. In average, BJHS patients suffered from joint pain in 8.53 joints in the last 3 months, opposed to 0.77 joints in the control group. 58% of the BJHS patients, but non of the controls had considered themself ill. On a direct question, all those who regard themselves as ill pointed their joints as the reason for it, although 30% of them had extra articular manifestations. <h3>Conclusion</h3> Most of the people suffering from BJHS consider themselves ill. BJHS should be looked at as a disease by the Physician.
Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis
Authors: Akhilesh Jha, Ryan S. Thwaites, Tanushree Tunstall, Onn Min Kon, Robin J. Shattock, Trevor T. Hansel, Peter J.M. Openshaw
Journal: Journal of Allergy and Clinical Immunology (2020)
PNC¯27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML)
Authors: Huafeng Wang, Bin Zhang, Dandan Zhao, Estelle Troadec, Weixu Meng, Allen Lin, Anthony S. Stein, Monzr M. Al Malki, Herman Wu, Tinisha Mcdonald, Jie Jin, Guido Marcucci
Journal: Blood (2017)
A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder
Authors: Søren Egstrand, Anders Nordholm, Marya Morevati, Maria L. Mace, Alia Hassan, Tally Naveh-Many, Jakob L. Rukov, Eva Gravesen, Klaus Olgaard, Ewa Lewin
Journal: Kidney International (2020)

Circadian rhythms in metabolism, hormone secretion, cell cycle and locomotor activity are regulated by a molecular circadian clock with the master clock in the suprachiasmatic nucleus of the central nervous system. However, an internal clock is also expressed in several peripheral tissues. Although about 10% of all genes are regulated by clock machinery an internal molecular circadian clock in the parathyroid glands has not previously been investigated. Parathyroid hormone secretion exhibits a diurnal variation and parathyroid hormone gene promoter contains an E-box like element, a known target of circadian clock proteins. Therefore, we examined whether an internal molecular circadian clock is operating in parathyroid glands, whether it is entrained by feeding and how it responds to chronic kidney disease. As uremia is associated with extreme parathyroid growth and since disturbed circadian rhythm is related to abnormal growth, we examined the expression of parathyroid clock and clock-regulated cell cycle genes in parathyroid glands of normal and uremic rats. Circadian clock genes were found to be rhythmically expressed in normal parathyroid glands and this clock was minimally entrained by feeding. Diurnal regulation of parathyroid glands was next examined. Significant rhythmicity of fibroblast-growth-factor-receptor-1, MafB and Gata3 was found. In uremic rats, deregulation of circadian clock genes and the cell cycle regulators, Cyclin D1, c-Myc, Wee1 and p27, which are influenced by the circadian clock, was found in parathyroid glands as well as the aorta. Thus, a circadian clock operates in parathyroid glands and this clock and downstream cell cycle regulators are disturbed in uremia and may contribute to dysregulated parathyroid proliferation in secondary hyperparathyroidism.
IMPROVED SURVIVAL OF COLON CANCER DUE TO ADVANCES IN MANAGEMENT; A NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS 1989-2006
Authors: L.N. van Steenbergen, M.A.G. Elferink, P. Krijnen, V.E.P.P. Lemmens, S. Siesling, H.J.T. Rutten, H.E. Karim-Kos, J.W.W. Coebergh
Journal: Annals of Oncology (2010)
Plexus-specific retinal vascular anatomy and pathologies as seen by projection-resolved optical coherence tomographic angiography
Authors: Tristan T. Hormel, Yali Jia, Yifan Jian, Thomas S. Hwang, Steven T. Bailey, Mark E. Pennesi, David J. Wilson, John C. Morrison, David Huang
Journal: Progress in Retinal and Eye Research (2020)
Integrative transcriptome analysis deciphers mechanisms of nickel contact dermatitis
Authors: Lukas Wisgrill, Paulina Werner, Erja Jalonen, Angelika Berger, Antti Lauerma, Harri Alenius, Nanna Fyhrquist
Journal: Allergy (2020)

Abstract Background Nickel‐induced allergic contact dermatitis (nACD) remains a major occupational skin disorder, significantly impacting the quality of life of suffering patients. Complex cellular compositional changes and associated immunological pathways are partly resolved in humans; thus, the impact of nACD on human skin needs to be further elucidated. Methods To decipher involved immunological players and pathways, human skin biopsies were taken at 0, 2, 48, and 96 hours after nickel patch test in six nickel‐allergic patients. Gene expression profiles were analyzed via microarray. Results Leukocyte deconvolution of nACD‐affected skin identified major leukocyte compositional changes at 48 and 96 hours, including natural killer (NK) cells, macrophage polarization, and T‐cell immunity. Gene set enrichment analysis mirrored cellular‐linked functional pathways enriched over time. NK cell infiltration and cytotoxic pathways were uniquely found in nACD‐affected skin compared to sodium lauryl sulfate–induced irritant skin reactions. Conclusion These results highlight key immunological leukocyte subsets as well as associated pathways in nACD, providing insights into pathophysiology with the potential to unravel novel therapeutic targets.
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
Authors: Gerd R Burmester, Frank Buttgereit, Corrado Bernasconi, Jose M Álvaro-Gracia, Nidia Castro, Maxime Dougados, Cem Gabay, Jacob M van Laar, Jan Michael Nebesky, Attila Pethoe-Schramm, Carlo Salvarani, Marc Y Donath, Markus R John, Arnaud Constantin, Jacques Eric Gottenberg, Sylvie Loiseau-Peres, Minh Nguyen, Thierry Schaeverbeke, Rieke H.-E. Alten, Christopher Amberger, Werner A. Biewer, Konrad Boche, Gerd Ruediger Burmester, Andreas Engel, Martin Feuchtenberger, Martin Fleck, Georg Gauler, Bernhard Heilig, Maria Höhle, Christof Iking-Konert, Peter Kästner, David Kofler, Klaus Krueger, Cornelia Kühne, Reiner Kurthen, Hendrik Schulze-Koops, Holger Schwenke, Maren Sieburg, Christof Specker, Hans-Peter Tony, Siegfried Wassenberg, Jörg Wendler, Roberto Caporali, Oscar Epis, Marco Matucci-Cerinic, Carlo Salvarani, Alexander Dubikov, Rimma Kamalova, Maxim Korolev, Vadim I. Mazurov, Ekaterina Puntus, Nemanja Damjanov, Tatjana Ilic, Milijanka Lazarevic, Sasa Milenkovic, Milan Petronijevic, Cem Gabay, Elyes Bouajina, Mohamed Elleuch
Journal: The Lancet (2020)
Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID‐19: Systematic Review and Meta‐analysis
Authors: Alexander J. Kovalic, Glen Huang, Paul J. Thuluvath, Sanjaya K. Satapathy
Journal: Hepatology (2020)

Background and Aims Several recent studies have reported an abnormal liver chemistry profile among patients with coronavirus disease 2019 (COVID‐19), although its clinical significance remains unknown. Approach and Results This systematic review and meta‐analysis identified six studies of 586 patients delineating liver chemistries among patients with severe/critical illness versus mild cases of COVID‐19 infection. Patients with severe/critical illness with COVID‐19 infection have increased prevalence of coronary artery disease, cerebrovascular disease, and chronic obstructive pulmonary disease as compared with mild cases. A significant association between severe/critical COVID‐19 infections with elevations in aspartate aminotransferase (pooled mean difference [MD], 11.70 U/L; 95% confidence interval [CI], 2.97, 20.43; P = 0.009), elevated total bilirubin (pooled MD, 0.14 mg/dL; 95% CI, 0.06, 0.22; P = 0.0005), and decreased albumin (pooled MD, −0.68 g/L; 95% CI, −0.81, −0.55; P &lt; 0.00001) was noted. There was also a trend toward elevated alanine aminotransferase levels among these severe cases (pooled MD, 8.84 U/L; 95% CI, −2.28, 19.97; P = 0.12); however, this did not reach statistical significance. More severe/critically ill cases were associated with leukocytosis, neutrophilia, lymphopenia, elevated creatinine kinase, elevated lactate dehydrogenase (LDH), and elevated prothrombin time (PT). Conclusions Comorbidities, including coronary artery disease, cerebrovascular disease and chronic obstructive pulmonary disease, are more prevalent in hospitalized Chinese patients with severe/critical illness from COVID‐19, and these patients are more likely to manifest with abnormal liver chemistries. Further prospective studies are crucial to understand the pathophysiologic mechanisms underlying the hepatic manifestations of the novel COVID‐19 infection and its clinical significance.
Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients
Authors: Sonja Lang, Bradley Fairfied, Bei Gao, Yi Duan, Xinlian Zhang, Derrick E. Fouts, Bernd Schnabl
Journal: Gut Microbes (2020)

Background and Aims Alcoholic hepatitis is the most severe form of alcohol-related liver disease. While the gut microbiome is known to play a role in disease development and progression, less is known about specific compositional changes of the gut bacterial microbiome associated with disease severity. Therefore, the aim of our study was to correlate gut microbiota features with disease severity in alcoholic hepatitis patients.Methods We used 16S rRNA gene sequencing on fecal samples from 74 alcoholic hepatitis patients, which were enrolled at 9 centers in Europe, the United States, and Mexico in a multi-center observational study. The relative abundance of gut bacterial taxa on genus level, as well as the microbiome diversity, was correlated to various clinical, laboratory, and histologic parameters.Results We observed a negative correlation between the model for end-stage liver disease score and Shannon diversity, independent of potentially confounding factors (Padjust = 0.046). Alcoholic hepatitis patients with more severe disease had significantly decreased relative abundances of Akkermansia while the relative abundance of Veillonella was increased. We observed a reduction in the Bacteroides abundance (Padjust = 0.048) and Shannon diversity (Padjust = 0.018) in antibiotic-treated patients and patients receiving steroids had an increase in Veillonella abundance (Padjust = 0.005), which was both independent of potentially confounding factors.Conclusion We observed distinct changes in the gut bacterial microbiome of alcoholic hepatitis patients with more severe disease. The gut bacterial microbiome might be an attractive target to prevent and treat this deadly disease.
AB0227 Screening and diagnostic tests of tyroidal disfunction: activity of a rheumatology unit in a year of follow-up
Authors: MM Martinez-Losa, HC Macias, E Urgell, JR Espinosa, CD Lopez, CG Ferrer, JM Llobet, AR De la Serna
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Tyroidal disfunction has been widely related with autoimmune diseases and its prevalence is higher (23%) than the one described in normal population (10%). Tyroidal function tests are a common procedure in our rheumatological daily activity but protocols must be performed to detect cases at early onset. <h3>Objectives</h3> Screening tyroid tests and its diagnostic value in a Rheumatology Unit. <h3>Methods</h3> Between January and December (1998) 10.992 outpatients were visited in our Rheumatology Unit (range of age:18–91). Among them 602 tyroid function tests were performed (5.5%). Treatment with drugs that could interfere tyroidal function were also considered. <h3>Results</h3> A higher frequency of tyroid disfunction was observerd in hospitalised patients (31%) than in outpatients (13%)(p &lt; 0.05). The majority of new cases (14%;IC95:11–17%) were subclinical (12.5%;IC95:10–16%) and no significant differences were seen between groups of age (59) and sex. New cases described according to diagnostic: see Table 1 (RA: Rheumatoid Arthritis, SS: Sjögre Syndrom, Arth: Arthritis, Scl: Scleroderma, LES: Systemic Lupus Erythematosus, FM; Fybromialgia, OA: Osteoarthritis, Artg: Arthralgia, Mig: Mialgia, T. Disf: Tyroidal disfunction). <h3>Conclusion</h3> These results confirm that the study for tyroidal autoimmunity should be performed to clarify diagnosis, treatment and prognosis of this group of rheumatic patients due to its higher prevalence than in general population.
Cosmetic surgeon wins appeal against suspension from UK medical register
Authors: Clare Dyer
Journal: BMJ (2020)

A cosmetic surgeon has won an appeal against a decision to suspend him from the UK medical register after a High Court judge ruled that a finding that he offered a patient a discount for surgery was “procedurally flawed and untenable.”1

Mr Justice Warby also ruled that allegations of misconduct in 2009 against Ashish Dutta should never even have been brought before the medical practitioners tribunal. The charges related to conduct more than five years before the decision to investigate and the General Medical Council’s resolve to go ahead with them was “unlawful,” said Warby.

In April 2009 Dutta performed a breast augmentation operation on a woman referred to as Patient A. She had a follow-up scan in 2010 and Dutta referred her to another surgeon, Dr B. In 2014 she complained to Dutta that Dr B had indecently assaulted her. …
Abstract 13809: Splanchnic Congestion and the Everest Score for Assessing Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Authors: Nadia Bouabdallaoui, William Beaubien-Souligny, Essaid Oussaid, Christine Henri, Normand Racine, Andre Y Denault, Jean L Rouleau
Journal: Circulation (2019)

Introduction: Acute heart failure (AHF) accounts for 1-2% of all admissions in the US annually and 25% of these patients will be readmitted within 30 days. The EVEREST score has proven useful for r...
Abstract 16249: Increased All-Cause Mortality in Patients With Schizophrenia Following Acute Coronary Syndrome
Authors: Rubina Attar, Jan B Valentin, Phillip Freeman, Kristian Kragholm, Pontus Andell, Jørgen Aagaard, Svend Eggert Jensen
Journal: Circulation (2018)

Background: Being diagnosed with schizophrenia is associated with an increased risk of developing cardiovascular diseases such as Acute Coronary Syndrome (ACS). The aim of this study is to investig...
Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City
Authors: Roy M. Gulick, Magdalena E. Sobieszczyk, Donald W. Landry, Anthony N. Hollenberg
Journal: Journal of Clinical Investigation (2020)

Coronavirus disease 2019 , caused by SARS-CoV-2, was first recognized in Wuhan, China in December 2019 (1) and rapidly spread through Asia and Europe, with the first US case identified in January 2020.The first New York case was reported in early March 2020 and by the first week in April, the New York Presbyterian Hospital system, including Columbia and Weill Cornell, had close to 2500 in-patients with over 700 patients on ventilators.The standard of care for COVID-19 was supportive care only and with significant morbidity and mortality recognized, there was a desperate need to identify effective treatments.Launching clinical research studies during this public health crisis required communication, collaboration, prioritization, keeping current with rapidly changing evidence, and maintaining high standards of scientific integrity and participant safety.
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
Authors: Sylvie Tondeur, Franciane Paul, Jérémie Riou, Olivier Mansier, Dana Ranta, Lenaïg Le Clech, Eric Lippert, Suzanne Tavitian, Driss Chaoui, Mélanie Mercier, Benoit De Renzis, Laurane Cottin, Bruno Cassinat, Jean-Marie Chrétien, Jean-Christophe Ianotto, Olivier Allangba, Christophe Marzac, Laurent Voillat, Françoise Boyer, Corentin Orvain, Mathilde Hunault-Berger, François Girodon, Jean-Jacques Kiladjian, Valérie Ugo, Damien Luque Paz
Journal: Leukemia (2020)
The NCCN 2020 Virtual Annual Conference
Authors: Robert W. Carlson
Journal: Journal of the National Comprehensive Cancer Network (2020)

through 22-was one of the first major oncology meetings to be impacted by the coronavirus disease 2019 (COVID-19) pandemic.Ordinarily, NCCN would have welcomed some 1,500 participants, including oncologists, fellows, nurses, pharmacists, and other healthcare professionals, to Orlando, Florida, for an opportunity to learn from multidisciplinary experts and share perspectives with others.Although gathering in person was not possible this year, NCCN recognizes the importance of continuing optimal care and advancing new knowledge in oncology despite the COVID-19 pandemic.To facilitate this, NCCN is delivering the emerging findings and trends in cancer treatment via the NCCN 2020 Virtual Annual Conference (available at NCCN.org/conference).This special issue of JNCCN presents these Highlights as a synopsis of the virtual proceedings.Numerous innovations in cancer care have emerged over the past year, as reflected in continuous updates made to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).The webinars synopsized here provide essential new information on how to achieve the best outcomes for patients, and they also provide a deeper understanding of the strong evidence that supports recommendations found in the NCCN Guidelines.The breadth of topics presented reflect the impact NCCN and the NCCN Guidelines have on the management of people with cancer and support of their caregivers.Within the Virtual Conference, faculty from across the now 30 leading academic cancer centers that comprise NCCN presented the latest best practices in the treatment of patients with cancer and explained NCCN Guidelines updates for various malignancies.Topics in these Highlights include new and emerging therapies, keys to optimization and implementation of treatment, and best practices in delivery of care across the cancer continuum.Some sessions tackle issues where there are differing perspectives, including a panel on controversies in the management of hereditary cancers and a debate on optimal first-line therapy for chronic lymphocytic leukemia.Other sessions highlight updated evidence-based expert consensus for many cancer types (including breast, colon, lung, pancreatic, and many more).This Highlights issue also includes a selection of the abstracts from the NCCN General Poster Session, with studies focused on clinical oncology, preclinical oncology, epidemiology/risks, correlative/genetics, best practices in implementation and use of clinical practice guidelines, quality improvement, outcomes and health services research, and bioinformatics/information technology sciences.
Cardiovascular Health and Risk Management in Cancer Survivors
Authors: Javid J. Moslehi
Journal: Journal of the National Comprehensive Cancer Network (2020)

Cardio-oncology is a growing field, due to several factors. These include the recognition that similar risk factors predispose people to both cardiovascular disease and cancer. In addition, certain cancers affect the heart, and cancer treatments can have short-term and long-lasting deleterious effects on the cardiovascular system. More than 40 years ago, it became evident that anthracyclines and radiation cause heart damage, and since then the list of cancer treatments that can harm the cardiovascular system has grown to include more modern treatments, such as anti-HER2 agents and angiogenesis inhibitors. Most recently, immune checkpoint inhibitors (ICIs) have been added to the list of cancer treatments that cause cardiovascular damage. ICI-associated myocarditis is a relatively rare but fatal complication that develops rapidly after initiating immunotherapy. Oncologists should be aware of the potential cardiovascular complications of cancer treatments, and should assess the cardiovascular health of all patients about to undergo therapy. Cancer survivors should be assessed and advised about prevention and treatment that may be needed to address cardiovascular disease.